Cargando…

Enhancement of radiation response with bevacizumab

BACKGROUND: Vascular endothelial growth factor (VEGF) plays a critical role in tumor angiogenesis. Bevacizumab is a humanized monoclonal antibody that neutralizes VEGF. We examined the impact on radiation response by blocking VEGF signaling with bevacizumab. METHODS: Human umbilical vein endothelial...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoang, Tien, Huang, Shyhmin, Armstrong, Eric, Eickhoff, Jens C, Harari, Paul M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3537546/
https://www.ncbi.nlm.nih.gov/pubmed/22538017
http://dx.doi.org/10.1186/1756-9966-31-37
_version_ 1782254865483825152
author Hoang, Tien
Huang, Shyhmin
Armstrong, Eric
Eickhoff, Jens C
Harari, Paul M
author_facet Hoang, Tien
Huang, Shyhmin
Armstrong, Eric
Eickhoff, Jens C
Harari, Paul M
author_sort Hoang, Tien
collection PubMed
description BACKGROUND: Vascular endothelial growth factor (VEGF) plays a critical role in tumor angiogenesis. Bevacizumab is a humanized monoclonal antibody that neutralizes VEGF. We examined the impact on radiation response by blocking VEGF signaling with bevacizumab. METHODS: Human umbilical vein endothelial cell (HUVEC) growth inhibition and apoptosis were examined by crystal violet assay and flow cytometry, respectively. In vitro HUVEC tube formation and in vivo Matrigel assays were performed to assess the anti-angiogenic effect. Finally, a series of experiments of growth inhibition on head and neck (H&N) SCC1 and lung H226 tumor xenograft models were conducted to evaluate the impact of bevacizumab on radiation response in concurrent as well as sequential therapy. RESULTS: The anti-angiogenic effect of bevacizumab appeared to derive not only from inhibition of endothelial cell growth (40%) but also by interfering with endothelial cell function including mobility, cell-to-cell interaction and the ability to form capillaries as reflected by tube formation. In cell culture, bevacizumab induced a 2 ~ 3 fold increase in endothelial cell apoptosis following radiation. In both SCC1 and H226 xenograft models, the concurrent administration of bevacizumab and radiation reduced tumor blood vessel formation and inhibited tumor growth compared to either modality alone. We observed a siginificant tumor reduction in mice receiving the combination of bevacizumab and radiation in comparison to mice treated with bevacizumab or radiation alone. We investigated the impact of bevacizumab and radiation treatment sequence on tumor response. In the SCC1 model, tumor response was strongest with radiation followed by bevacizumab with less sequence impact observed in the H226 model. CONCLUSIONS: Overall, these data demonstrate enhanced tumor response when bevacizumab is combined with radiation, supporting the emerging clinical investigations that are combining anti-angiogenic therapies with radiation.
format Online
Article
Text
id pubmed-3537546
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35375462013-01-10 Enhancement of radiation response with bevacizumab Hoang, Tien Huang, Shyhmin Armstrong, Eric Eickhoff, Jens C Harari, Paul M J Exp Clin Cancer Res Research BACKGROUND: Vascular endothelial growth factor (VEGF) plays a critical role in tumor angiogenesis. Bevacizumab is a humanized monoclonal antibody that neutralizes VEGF. We examined the impact on radiation response by blocking VEGF signaling with bevacizumab. METHODS: Human umbilical vein endothelial cell (HUVEC) growth inhibition and apoptosis were examined by crystal violet assay and flow cytometry, respectively. In vitro HUVEC tube formation and in vivo Matrigel assays were performed to assess the anti-angiogenic effect. Finally, a series of experiments of growth inhibition on head and neck (H&N) SCC1 and lung H226 tumor xenograft models were conducted to evaluate the impact of bevacizumab on radiation response in concurrent as well as sequential therapy. RESULTS: The anti-angiogenic effect of bevacizumab appeared to derive not only from inhibition of endothelial cell growth (40%) but also by interfering with endothelial cell function including mobility, cell-to-cell interaction and the ability to form capillaries as reflected by tube formation. In cell culture, bevacizumab induced a 2 ~ 3 fold increase in endothelial cell apoptosis following radiation. In both SCC1 and H226 xenograft models, the concurrent administration of bevacizumab and radiation reduced tumor blood vessel formation and inhibited tumor growth compared to either modality alone. We observed a siginificant tumor reduction in mice receiving the combination of bevacizumab and radiation in comparison to mice treated with bevacizumab or radiation alone. We investigated the impact of bevacizumab and radiation treatment sequence on tumor response. In the SCC1 model, tumor response was strongest with radiation followed by bevacizumab with less sequence impact observed in the H226 model. CONCLUSIONS: Overall, these data demonstrate enhanced tumor response when bevacizumab is combined with radiation, supporting the emerging clinical investigations that are combining anti-angiogenic therapies with radiation. BioMed Central 2012-04-26 /pmc/articles/PMC3537546/ /pubmed/22538017 http://dx.doi.org/10.1186/1756-9966-31-37 Text en Copyright ©2012 Hoang et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Hoang, Tien
Huang, Shyhmin
Armstrong, Eric
Eickhoff, Jens C
Harari, Paul M
Enhancement of radiation response with bevacizumab
title Enhancement of radiation response with bevacizumab
title_full Enhancement of radiation response with bevacizumab
title_fullStr Enhancement of radiation response with bevacizumab
title_full_unstemmed Enhancement of radiation response with bevacizumab
title_short Enhancement of radiation response with bevacizumab
title_sort enhancement of radiation response with bevacizumab
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3537546/
https://www.ncbi.nlm.nih.gov/pubmed/22538017
http://dx.doi.org/10.1186/1756-9966-31-37
work_keys_str_mv AT hoangtien enhancementofradiationresponsewithbevacizumab
AT huangshyhmin enhancementofradiationresponsewithbevacizumab
AT armstrongeric enhancementofradiationresponsewithbevacizumab
AT eickhoffjensc enhancementofradiationresponsewithbevacizumab
AT hararipaulm enhancementofradiationresponsewithbevacizumab